- Home
- RNAZ vs CPHI Comparison
RNAZ vs CPHI Comparison
Compare RNAZ & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- CPHI
- Stock Information
- Founded
- RNAZ 2016
- CPHI N/A
- Country
- RNAZ United States
- CPHI China
- Employees
- RNAZ N/A
- CPHI N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- CPHI Health Care
- Exchange
- RNAZ Nasdaq
- CPHI Nasdaq
- Market Cap
- RNAZ 4.9M
- CPHI 4.2M
- IPO Year
- RNAZ 2021
- CPHI N/A
- Fundamental
- Price
- RNAZ $3.84
- CPHI $0.18
- Analyst Decision
- RNAZ Strong Buy
- CPHI
- Analyst Count
- RNAZ 1
- CPHI 0
- Target Price
- RNAZ $99.00
- CPHI N/A
- AVG Volume (30 Days)
- RNAZ 30.4K
- CPHI 307.1K
- Earning Date
- RNAZ 11-14-2024
- CPHI 11-13-2024
- Dividend Yield
- RNAZ N/A
- CPHI N/A
- EPS Growth
- RNAZ N/A
- CPHI N/A
- EPS
- RNAZ N/A
- CPHI N/A
- Revenue
- RNAZ N/A
- CPHI $5,544,620.00
- Revenue This Year
- RNAZ N/A
- CPHI N/A
- Revenue Next Year
- RNAZ $233.33
- CPHI N/A
- P/E Ratio
- RNAZ N/A
- CPHI N/A
- Revenue Growth
- RNAZ N/A
- CPHI N/A
- 52 Week Low
- RNAZ $6.31
- CPHI $0.13
- 52 Week High
- RNAZ $264.00
- CPHI $0.70
- Technical
- Relative Strength Index (RSI)
- RNAZ 23.15
- CPHI 46.97
- Support Level
- RNAZ $6.63
- CPHI $0.13
- Resistance Level
- RNAZ $8.46
- CPHI $0.20
- Average True Range (ATR)
- RNAZ 1.04
- CPHI 0.02
- MACD
- RNAZ -0.25
- CPHI 0.00
- Stochastic Oscillator
- RNAZ 1.65
- CPHI 80.38
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.